Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men

The pharmacokinetic dose linearity and reproducibility, the effects on ex-vivo coagulation time assays and bleeding time, and tolerability of the direct thrombin inhibitor melagatran following subcutaneous (s.c.) dosing were investigated in two open-label studies in healthy males: (i) a dose-escalation study in which subjects received single s.c. doses of melagatran (0.1–5 mg); and (ii) a repeated-dosing study in which 3 mg s.c. melagatran was administered at 12-h intervals for 4 days. In both studies, melagatran was rapidly absorbed with maximum plasma concentrations (Cmax) observed about 0.5 h post dosing. The half-life of melagatran was about 2 h. The area under the melagatran plasma concentration versus time curve increased linearly with dose. No time dependency in the area under the curve or Cmax was observed over 4 days of twice-daily dosing. The variability in pharmacokinetic parameters was low and the bioavailability of melagatran appeared to be complete. There was a steep and linear prolongation of thrombin time, a non-linear prolongation of both activated partial thromboplastin time and activated coagulation time, and a decrease in prothrombin complex activity with increasing melagatran plasma concentration. Only moderate increases in capillary bleeding time were observed with s.c. doses up to 5 mg melagatran. Melagatran was well tolerated after s.c. injection, with good local tolerability at the injection site.

[1]  Stig L Boström,et al.  Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[2]  P. Petersen,et al.  Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation , 2003 .

[3]  J. Badimón,et al.  Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r‐hirudin in a human ex vivo model of arterial thrombosis , 2003, Journal of thrombosis and haemostasis : JTH.

[4]  U. Bredberg,et al.  Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[5]  C. Mattsson,et al.  Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[6]  S. Schulman,et al.  A randomized, controlled, dose‐guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I , 2003, Journal of thrombosis and haemostasis : JTH.

[7]  B. Eriksson,et al.  Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial , 2002, The Lancet.

[8]  C. Francis,et al.  Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty , 2002, Annals of Internal Medicine.

[9]  J. Harenberg,et al.  Influence of lepirudin, argatroban, and melagatran on prothrombin time and additional effect of oral anticoagulation. , 2002, Clinical chemistry.

[10]  L. Lapidus,et al.  Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. , 2002, Thrombosis research.

[11]  J. Harenberg,et al.  Monitoring of Anticoagulant Effects of Direct Thrombin Inhibitors , 2002, Seminars in thrombosis and hemostasis.

[12]  B. Eriksson,et al.  Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies. , 2002, Thrombosis research.

[13]  M. Wolzt,et al.  Inhibition of Thrombin Generation by the Oral Direct Thrombin Inhibitor Ximelagatran in Shed Blood from Healthy Male Subjects , 2002, Thrombosis and Haemostasis.

[14]  B. Eriksson,et al.  A Dose-ranging Study of the Oral Direct Thrombin Inhibitor, Ximelagatran, and Its Subcutaneous Form, Melagatran, Compared with Dalteparin in the Prophylaxis of Thromboembolism after Hip or Knee Replacement: METHRO I , 2002, Thrombosis and Haemostasis.

[15]  M. Ahnoff,et al.  Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[16]  C. Colwell,et al.  Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. , 2001, Archives of internal medicine.

[17]  T. Lindahl,et al.  Effect of Melagatran on Prothrombin Time Assays Depends on the Sensitivity of the Thromboplastin and the Final Dilution of the Plasma Sample , 2001, Thrombosis and Haemostasis.

[18]  D. Gustafsson,et al.  The effects of oral and intravenous direct thrombin inhibitors on the size of photochemically induced cortical infarction in rats. , 2001, Thrombosis research.

[19]  A Abrahamsson,et al.  The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. , 2001, Thrombosis research.

[20]  S. Carlsson,et al.  Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. , 1999, Thrombosis research.

[21]  J. Stürzebecher,et al.  Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. , 1999, Thrombosis research.

[22]  P. Held,et al.  Pharmacokinetics and Pharmacodynamics of Melagatran, a Novel Synthetic LMW Thrombin Inhibitor, in Patients with Acute DVT , 1999, Thrombosis and Haemostasis.

[23]  T. Saldeen,et al.  Melagatran, a Low Molecular Weight Thrombin Inhibitor, Counteracts Endotoxin-induced Haemodynamic and Renal Dysfunctions in the Pig , 1998, Thrombosis and Haemostasis.

[24]  J. Mehta,et al.  Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. , 1998, Journal of cardiovascular pharmacology.

[25]  B. Eriksson,et al.  Antithrombotic Effect of Two Low Molecular Weight Thrombin Inhibitors and a Low-Molecular Weight Heparin in a Caval Vein Thrombosis Model in the Rat , 1997, Thrombosis and Haemostasis.

[26]  J. Deinum,et al.  The Importance of Enzyme Inhibition Kinetics for the Effect of Thrombin Inhibitors in a Rat Model of Arterial Thrombosis , 1997, Thrombosis and Haemostasis.

[27]  V. Tapson,et al.  Management of venous thromboembolic disease. The impact of low-molecular-weight heparin. , 1995, Clinics in chest medicine.

[28]  G. Claeson Synthetic peptides and peptidomimetics as substrates and inhibitors of thrombin and other proteases in the blood coagulation system. , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[29]  T. Barrowcliffe,et al.  Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration. , 1976, Thrombosis research.

[30]  P. Petersen,et al.  Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. , 2003, Journal of the American College of Cardiology.

[31]  B. Eriksson,et al.  A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. , 2002, Thrombosis and haemostasis.

[32]  S. Pehrsson,et al.  Effects of Melagatran, a New Low-molecular-weight Thrombin Inhibitor, on Thrombin and Fibrinolytic Enzymes , 1998, Thrombosis and Haemostasis.

[33]  P. Owren,et al.  The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. , 1951, Scandinavian journal of clinical and laboratory investigation.